V. Labonia

Adjuvant anastrozole versus exemestane versus letrozole, upfront or after 2 years of tamoxifen, in endocrine-sensitive breast cancer (FATA-GIM3): a randomised, phase 3 trial

Sabino De Placido, Ciro Gallo, Michelino De Laurentiis et al. · The Lancet Oncology · 2018 · 88 citations · Full text

Medicine, Endocrinology, Oncology +11

Endocrine Effects of Adjuvant Letrozole Compared With Tamoxifen in Hormone-Responsive Postmenopausal Patients With Early Breast Cancer: The HOBOE Trial

Emanuela Rossi, Alessandro Morabito, Francesca Di Rella et al. · Journal of Clinical Oncology · 2009 · 80 citations

Medicine, Endocrinology, Oncology +17

Weekly docetaxel versus CMF as adjuvant chemotherapy for older women with early breast cancer: final results of the randomized phase III ELDA trial

Francesco Perrone, Francesco Nuzzo, Francesca Di Rella et al. · Annals of Oncology · 2014 · 68 citations · Full text

Medicine, Geriatric Medicine, Oncology +12

Docetaxel plus epidoxorubicin as neoadjuvant treatment in patients with large operable or locally advanced carcinoma of the breast

A. De Matteis, Francesco Nuzzo, Giuseppe D’Aiuto et al. · Cancer · 2002 · 56 citations · Full text

Medicine, Oncology, Pharmacology +15

Endocrine Effects of Adjuvant Letrozole + Triptorelin Compared With Tamoxifen + Triptorelin in Premenopausal Patients With Early Breast Cancer

Emanuela Rossi, Alessandro Morabito, Ermelinda De Maio et al. · Journal of Clinical Oncology · 2007 · 44 citations

Medicine, Endocrinology, Oncology +17